X4 Pharmaceuticals Inc (XFOR) concluded trading on Thursday at a closing price of $1.83, with 15.47 million shares of worth about $28.3 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -87.50% during that period and on July 24, 2025 the price saw a gain of about 22.00%. Currently the company’s common shares owned by public are about 5.79M shares, out of which, 3.84M shares are available for trading.
Stock saw a price change of 22.82% in past 5 days and over the past one month there was a price change of -20.43%. Year-to-date (YTD), XFOR shares are showing a performance of -92.35% which decreased to -91.68% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.38 but also hit the highest price of $26.96 during that period. The average intraday trading volume for X4 Pharmaceuticals Inc shares is 448.95K. The stock is currently trading 10.21% above its 20-day simple moving average (SMA20), while that difference is down -28.72% for SMA50 and it goes to -82.33% lower than SMA200.
X4 Pharmaceuticals Inc (NASDAQ: XFOR) currently have 5.79M outstanding shares and institutions hold larger chunk of about 31.41% of that.
The stock has a current market capitalization of $10.59M and its 3Y-monthly beta is at 0.59. PE ratio of stock for trailing 12 months is 0.82, while it has posted earnings per share of $2.24 in the same period. It has Quick Ratio of 3.58 while making debt-to-equity ratio of 3.40. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for XFOR, volatility over the week remained 15.53% while standing at 11.47% over the month.
Stock’s fiscal year EPS is expected to drop by -55.05% while it is estimated to increase by 0.77% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by B. Riley Securities on December 12, 2023 offering a Neutral rating for the stock and assigned a target price range of between $3 and $1 to it. Coverage by B. Riley Securities stated X4 Pharmaceuticals Inc (XFOR) stock as a Buy in their note to investors on August 30, 2023, suggesting a price target of $3 for the stock. On December 22, 2022, Cantor Fitzgerald Initiated their recommendations, while on December 12, 2022, Piper Sandler Initiated their ratings for the stock with a price target of $3. Stock get an Outperform rating from Oppenheimer on December 23, 2019.
